Trevena ’s stock slides after safety concerns raised about new drug candidate

Trevena ’s stock closed down 64 percent Tuesday after Food and Drug Administration review staff raised potential safety concerns about the Chesterbrook, Pa., biopharmaceutical company’s lead drug candidate. The new drug candidate for severe-to-moderate pain in patients in need of an intravenous opioid treatment has the proposed brand name Olinvo and the active ingredient oliceridine. In background materials prepared for the agency’s Anesthetic and Analgesic Drug Products Advisory Committee…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news